Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on hormone secretion from sheep pituitary cells in vitro

Journal of Neuroendocrinology

Volumn 9, Issue 4, 1997, Pages 279-286

  Sawangjaroen, K ^a,b   Anderson, S T ^a   Curlewis, J D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Anterior pituitary; FSH; GH; LH; PACAP; Prolactin; VIP

Indexed keywords

CYCLIC AMP; DOPAMINE; FOLLITROPIN; GONADORELIN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS HORMONE; LUTEINIZING HORMONE; PROLACTIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; FOLLITROPIN RELEASE; GROWTH HORMONE RELEASE; HYPOPHYSIS CELL; LUTEINIZING HORMONE RELEASE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN RELEASE; SHEEP;

EID: 0030990919     PISSN: 09538194     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2826.1997.00580.x     Document Type: Article

References (48)

1. Mezey E, Kiss JZ. Vasoactive intestinal peptide-containing neurons in the paraventricular nucleus may participate in regulating prolactin secretion. Proc Natl Acad Sci USA 1985; 82: 245-247.
2. Ceccatelli S, Fahrenkrug J, Villar MJ, Hökfelt T. Vasoactive intestinal polypeptide/peptide histidine isoleucine immunoreactive neuron systems in the basal hypothalamus of the rat with special reference to the portal vasculature: an immunohistochemical and in situ hybridization study. Neuroscience 1991; 43: 483-502.
3. Shimatsu A, Kato Y, Inoue T, Christofides ND, Bloom SR, Imura H. Peptide histidine isoleucine-and vasoactive intestinal polypeptide-like immunoreactivity coexist in rat hypophysial portal blood. Neurosci Lett 1983; 43: 259-262.
4. Kato Y, Iwasaki Y, Iwasaki J, Abe H, Yanaihara N, Imura H. Prolactin release by vasoactive intestinal polypeptide in rats. Endocrinology 1978; 103: 554-558.
5. Enjalbert A, Arancibia S, Ruberg M, Priam M, Bluet-Pajot MT, Rotsztejn WH, Kordon C. Stimulation of in vitro prolactin release by vasoactive intestinal peptide. Neuroendocrinology 1980; 31: 200-204.
6. Rotsztejn WH, Benoist L, Besson J, Berand G, Bluet-Pajot MT, Kordon C, Rosselin G, Duval J. Effect of vasoactive intestinal peptide (VIP) on the release of adenohypophyseal hormones from purified cells obtained by unit gravity sedimentation. Neuroendocrinology 1980; 31: 282-286.
7. Rawlings SR, Piuz I, Schlegel W, Bockaert J, Journot L. Differential expression of pituitary adenylate cyclase-activating polypeptide/ vasoactive intestinal polypeptide receptor subtypes in clonal pituitary somatotrophs and gonadotrophs. Endocrinology 1995; 136: 2088-2098.
8. Bjoro T, Ostberg BC, Sand O, Gordeladze J, Iversen JG, Torjesen PA, Gautvik KM, Haug E. Vasoactive intestinal peptide and peptide with N-terminal histidine and C-terminal isoleucine increase prolactin secretion in cultured rat pituitary cells (GH4C1) via a cAMP-dependent mechanism which involves transient elevation of intracellular Ca2+. Mol Cell Endocrinol 1987; 49: 119-128.
9. Pizzi M, Memo M, Benarese M, Simonazzi E, Missale C, Spano PF. A mechanism additional to cyclic AMP accumulation for vasoactive intestinal peptide-induced prolactin release. Neuroendocrinology 1990; 51: 481-486.
10. Abe H, Engler D, Molitch ME, Gruber JB, Reichlin S. Vasoactive intestinal peptide is a physiological mediator of prolactin release in the rat. Endocrinology 1985; 116: 1383-1390.
11. el Halawani ME, Silsby JL, Mauro LJ. Vasoactive intestinal peptide is a hypothalamic prolactin-releasing neuropeptide in the turkey (Meleagris gallopavo). Gen Comp Endocrinol 1990; 78: 66-73.
12. Kato Y, Shimatsu A, Matsushita N, Ohta H, Imura H. Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man. Peptides 1984; 5: 389-394.
13. Clarke I, Jessop D, Millar R, Morris M, Bloom S, Lightman S, Coen CW, Lew R, Smith I. Many peptides that are present in the external zone of the median eminence are not secreted into the hypophysial portal blood of sheep. Neuroendocrinology 1993; 57: 765-775.
14. Thomas GB, Cummins JT, Griffin N, Clarke IJ. Effect and site of action of hypothalamic neuropeptides on prolactin release in sheep. Neuroendocrinology 1988; 48: 252-257.
15. Sawangjaroen K, Curlewis JD. Effects of pituitary adenylate cyclase-activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on prolactin, luteinizing hormone and growth hormone secretion in the ewe. J Neuroendocrinol 1994; 6: 549-555.
16. Sawangjaroen K, Sernia C, Curlewis JD. Effects of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on cyclic AMP accumulation in sheep pituitary cells in vitro. J Endocrinol 1996; 148: 545-552.
17. Köves K, Arimura A, Somogyvari Vigh A, Vigh S, Miller J. Immunohistochemical demonstration of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, in the ovine hypothalamus. Endocrinology 1990; 127: 264-271.
18. Vigh S, Arimura A, Köves K. Somogyvari Vigh A, Sitton J, Fermin CD. Immunohistochemical localization of the neuropeptide, pituitary adenylate cyclase activating polypeptide (PACAP), in human and primate hypothalamus. Peptides 1991; 12: 313-318.
19. Mikkelsen JD, Hannibal J, Fahrenkrug J, Larsen PJ, Olcese J, McArdle C. Pituitary adenylate cyclase activating peptide-38 (PACAP-38), PACAP-27, and PACAP related peptide (PRP) in the rat median eminence and pituitary. J Neuroendocrinol 1995; 7: 47-55.
20. Kimura S, Ohshige Y, Lin L, Okumura T, Yanaihara C, Yanaihara N, Shiotani Y. Localization of pituitary adenylate cyclase-activating polypeptide (PACAP) in the hypothalamus-pituitary system in rats: light and electron microscopic immunocytochemical studies. J Neuroendocrinol 1994; 6: 503-507.
21. Dow RC, Bennie J, Fink G. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol 1994; 142: R1-R4.
22. Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH. Isolation of a novel residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 1989; 164: 567-574.
23. Chartrel N, Tonon MC, Vaudry H, Conlon JM. Primary structure of frog pituitary adenylate cyclase-activating polypeptide (PACAP) and effects of ovine PACAP on frog pituitary. Endocrinology 1991; 129: 3367-3371.
24. Onali P and Olianas MC. PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species. Brain Res 1994; 641: 132-134.
25. Hoshino M, Li M, Zheng LQ, Suzuki M, Mochizuki T, Yanaihara N. Pituitary adenylate cyclase activating peptide and vasoactive intestinal polypeptide: differentiation effects on human neuroblastoma NB-OK-1 cells. Neurosci Lett 1993; 159: 35-38.
26. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, Journot L. Differential signal transduction by five splice variants of the PACAP receptor. Nature 1993; 365: 170-175.
27. Jarry H, Leonhardt S, Schmidt WE, Creutzfeldt W, Wuttke W. Contrasting effects of pituitary adenylate cyclase activating polypeptide (PACAP) on in vivo and in vitro prolactin and growth hormone release in male rats. Life Sci 1992; 51: 823-830.
28. Leonhardt S, Jarry H, Kreipe A, Werstler K, Wuttke W. Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates pituitary hormone release in male rats. Neuroendocrinol Lett 1992; 14: 319-328.
29. Hart GR, Gowing H and Burrin JM. Effects of a novel hypothalamic peptide, pituitary adenylate cyclase-activating polypeptide, on pituitary hormone release in rats. J Endocrinol 1992; 134: 33-41.
30. Culler MD, Paschall CS. Pituitary adenylate cyclase-activating polypeptide (PACAP) potentiates the gonadotropin-releasing activity of luteinizing hormone-releasing hormone. Endocrinology 1991; 129: 2260-2262.
31. Macrae AD, Gilbey SG, Mould MA, Bloom SR. PACAP: cardiovascular and endocrine actions in man. J Endocrinol 1991; 129 Suppl.: Abstr 173-Abstr 170.
32. Dostmann WR, Taylor SS, Genieser HG, Jastorff B, Doskeland SO, Ogreid D. Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3′,5′-cyclic phosphorothioates. J Biol Chem 1990; 265: 10484-10491.
33. Rothermel JD, Parker Botelho LH. A mechanistic and kinetic analysis of the interactions of the diastereomers of adenosine 3′,5′-(cyclic)phosphorothioate with purified cyclic AMP-dependent protein kinase. Biochem J 1988; 251: 757-762.
34. Grider JR, Katsoulis S, Schmidt WE, Jin JG. Regulation of the descending relaxation phase of intestinal peristalsis by PACAP. J Auton Nerv Syst 1994; 50: 151-159.
35. Law GJ, Ray KP, Wallis M. Effects of growth hormone-releasing factor and somatostatin on growth hormone secretion and cellular cyclic AMP levels: Cultured ovine and rat anterior pituitary cells show markedly different responses. FEBS Lett 1985; 179: 12-16.
36. i. Endocrinology 1991; 128: 570-582.
37. Chen C and Clarke IJ. Modulation of Ca2+ influx in the ovine somatotroph by growth hormone-releasing factor. Am J Physiol 1995; 268: E204-E212.
38. Armstrong D, Eckert R. Voltage-activated calcium channels that must be phosphorylated to respond to membrane depolarization. Proc Natl Acad Sci USA 1987; 84: 2518-2522.
39. i) and growth hormone release from purified rat somatotrophs. III. Mechanism of action of GH-releasing factor and somatostatin. Endocrinology 1991; 128: 592-603.
40. Wu D, Chen C, Clarke IJ. The functional relationship of protein kinase C (PKC) activity translocation and growth hormone (GH) release by GH-releasing factor (GHRH) and GH-releasing peptides (GHRP-2 and GHRP-6). Abstracts No. 92. The Endocrine Society of Australia Proceedings 1995; 38: 101.
41. 2+ channels: evidence for direct regulation independent of phosphorylation by cAMP- dependent protein kinase or stimulation by a dihydropyridine agonist. J Biol Chem 1988; 263: 9887.
42. 2+ in rat gonadotropes and somatotropes through different intracellular mechanisms. Endocrinology 1993; 132: 1447-1452.
43. Christophe J, Svoboda M, Dehaye J-P, Winand J, Vandermeers-Pire MC, Vandermeers A, Cauvin A, Gourlet P, Robberecht P. The VIP/PHI/secretin/helodermin/helospectin/GHRH family: structure-function relationship of the natural peptides, their precursors and synthetic analogues as tested in vitro on receptors and adenylate cyclase in a panel of tissue membranes. In: Martinez J, ed. Peptide hormones as prohormones: Processing, Biological activity, Pharmacology, Chichester: Ellis Horwood Limited, 1989: 211-243.
44. Waelbroeck M, Robberecht P, Coy DH, Camus J-C, DeNeef P, Christophe J. Interaction of growth hormone-releasing factor (GRF) and 14 GRFanalogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology 1985; 116: 2643-2649.
45. Goth MI, Lyons CE, Canny BJ, Thorner MO. Pituitary adenylate cyclase-activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992; 130: 939-944.
46. Rawlings SR, Hezareh M. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP: Vasoactive intestinal polypeptide receptors: actions on the anterior pituitary gland. Endocr Rev 1996; 17: 4-29.
47. Murakami Y, Koshimura K, Yamauchi K, Nishiki M, Tanaka J, Furuya H, Miyake T, Kato Y. Pituitary adenylate cyclase activating polypeptide (PACAP) stimulates growth hormone release from GH3 cells through type II PACAP receptor. Regul Pept 1995; 56: 35-40.
48. McNeilly AS. Changes in FSH and the pulsatile secretion of LH during the delay in oestrus induced by treatment of ewes with bovine follicular fluid. J Reprod Fertil 1984; 72: 165-172.